Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/30/2021 (updated 4/5/2024)
This toolkit provides correctional administrators and health care providers the information necessary to plan and implement MAT programs within jails and prisons.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/24/2020 (updated 3/28/2024)
AgriSafe is a national non profit that offers occupational health and safety training for rural health professionals. Currently AgriSafe in partnership with Mississippi State University Extension and University of Mississippi Medical Center are offering Continuing Health Professional Education through four webinars listed below. One hour of continuing education is available for each webinar.
This continuing education opportunity is free to licensed health care providers in the state of Mississippi. For health care providers outside of Mississippi, the continuing education is available for $40 per CE hour.
Posted 3/7/2023 (updated 3/27/2024)
n December 2022, Congress eliminated the DATA-Waiver program registration allowing providers to prescribe buprenorphine to treat patients for OUD. The University of Vermont Center on Rural Addiction, a HRSA Rural Center of Excellence on Substance Use Disorders, offers an incentive to help defray previous training costs of $750 to each qualifying provider who obtained a DATA-Waiver. To qualify, providers must be practicing in a HRSA-designated rural county in Vermont, Maine, New Hampshire, or Northern New York.
Posted 12/21/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration released a notice of proposed rulemaking that would allow certified opioid treatment programs to begin prescribing the drug via audio-only or video-enabled telehealth. See additional information under Policy Updates below. The proposed changes come on top of recent findings by HHS of the positive impact of its revised Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that removed two longstanding requirements for obtaining a waiver to treat up to 30 patients with buprenorphine: 1) the requirement for specific training, and 2) the need for otherwise eligible clinicians to certify their ability to provide or refer patients for counseling and other services. Rural primary care providers have obtained the DEA waiver at a lower rate than urban clinicians; decreased burden and greater flexibility in the guidelines, along with broader use of telehealth could help close that gap.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 4/20/2022 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration-funded Opioid Response Network (ORN) initiative has launched the Stand Against Stigma (SAS) Challenge. This is an opportunity for those in the healthcare industry to address and dispel stigma related to individuals with substance use disorders through easy, daily activity.